FDA Moves to Initiate Comprehensive Review of Moderna's mRNA-1010 Flu Vaccine; Stock Surges

Moderna has achieved a significant regulatory milestone. The company announced that the U.S. FDA will formally initiate its review of the Biologics License Application (BLA) for mRNA-1010, the company’s investigational messenger RNA-based seasonal influenza vaccine. This decision follows a constructive Type A meeting between Moderna and FDA officials, representing a crucial turning point after the agency’s previous Refusal-to-File (RTF) determination.

Breaking the Regulatory Deadlock: Strategic Path Forward

The journey to this point underscores the complexity of vaccine development. After receiving the RTF letter, Moderna restructured its regulatory strategy and resubmitted with a refined approach. The company now seeks full approval for adults aged 50 to 64, while simultaneously pursuing accelerated approval for adults 65 and older. As a condition of moving forward, Moderna must conduct an additional post-marketing study focusing on the older adult population. The FDA has assigned an ambitious PDUFA goal date of August 5, 2026, providing a clear timeline for the regulatory decision.

Tiered Approval Strategy Addresses Multiple Demographics

The dual-track approval pathway reflects modern regulatory thinking. If approved as planned, mRNA-1010 will be available for U.S. adults aged 50 and above during the 2026/2027 influenza season. The differentiated approach for separate age cohorts demonstrates how vaccine developers now tailor safety and efficacy data to specific population segments. This represents a shift from one-size-fits-all regulatory submissions to more sophisticated risk-benefit stratifications based on immunological and epidemiological data.

Expanding Beyond U.S. Borders

The regulatory momentum extends globally. mRNA-1010 is simultaneously undergoing review in Europe, Canada, and Australia, with additional submissions planned throughout 2026. Moderna has signaled expectations for the first international approvals later this year, positioning the company to potentially launch in multiple markets before the U.S. approval target date. This parallel regulatory strategy demonstrates the company’s confidence in the vaccine candidate’s profile.

Market Response and Forward-Looking Sentiment

The market has responded positively to the regulatory progress. Moderna shares (MRNA) recently advanced significantly, with the stock trading up over 8% in recent sessions, reflecting investor optimism about the vaccine’s approval prospects. The company has traded in a range between $22.28 and $55.20 over the twelve-month period. CEO Stéphane Bancel emphasized that Moderna values the FDA’s collaborative approach and remains committed to delivering an innovative flu vaccine option for American adults potentially as early as 2026.

The initiation of FDA review marks a pivotal moment in mRNA-1010’s development trajectory, suggesting the regulatory pathway has stabilized after earlier setbacks. With the August 2026 goal date in sight and international submissions advancing, Moderna appears positioned to expand its vaccine portfolio beyond COVID-19 therapeutics into seasonal influenza protection.